Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-5412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-248 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-204 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6869 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
filingDate |
2016-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2022-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2022-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-107530431-B |
titleOfInvention |
Biomarkers |
abstract |
The present invention relates to methods of treating chronic intestinal inflammation and/or inflammatory bowel disease by administering antagonists of oncostatin-M (OSM) and/or OSM receptor-beta (OSMR). The invention also relates to methods for the diagnostic or prognostic prediction of chronic intestinal inflammation and/or inflammatory bowel disease in an individual and for predicting whether an individual will respond to anti-TNF α therapy. The method comprises measuring OSM and/or OSMR in the individual. |
priorityDate |
2015-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |